Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Erratum: Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma.
Journal: JCO precision oncology
Published: July 16, 2026
Multi-Institutional Study Evaluating the Role of Early Circulating Tumor DNA Dynamics During Treatment With Immune Checkpoint Inhibitors in Patients With Advanced-Stage Melanoma.
Journal: JCO precision oncology
Published: February 13, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.
Journal: Cancer discovery
Published: October 07, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma.
Journal: NPJ precision oncology
Published: August 20, 2024
A SDHB Variant of Unknown Significance in a Patient With a Cardiac Functional Paraganglioma.
Journal: JCEM case reports
Published: December 01, 2022
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
Journal: Journal for immunotherapy of cancer
Published: July 01, 2021
Persistent Rivaroxaban Effect Due to Impaired Renal Clearance and Medication Effects.
Journal: Laboratory medicine
Published: July 25, 2019
Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience.
Journal: Journal of geriatric oncology
Published: August 08, 2018
Management of melanoma in patients with chronic lymphocytic leukemia.
Journal: Leukemia research
Published: May 25, 2018
Showing 1-11 of 11
Last Updated: 09/26/2026